Package: RobinCar2 0.2.2.9000

RobinCar2: ROBust INference for Covariate Adjustment in Randomized Clinical Trials

Performs robust estimation and inference when using covariate adjustment and/or covariate-adaptive randomization in randomized controlled trials. This package is trimmed to reduce the dependencies and validated to be used across industry. See "FDA's final guidance on covariate adjustment"<https://www.regulations.gov/docket/FDA-2019-D-0934>, Tsiatis (2008) <doi:10.1002/sim.3113>, Bugni et al. (2018) <doi:10.1080/01621459.2017.1375934>, Ye, Shao, Yi, and Zhao (2023)<doi:10.1080/01621459.2022.2049278>, Ye, Shao, and Yi (2022)<doi:10.1093/biomet/asab015>, Rosenblum and van der Laan (2010)<doi:10.2202/1557-4679.1138>, Wang et al. (2021)<doi:10.1080/01621459.2021.1981338>, Ye, Bannick, Yi, and Shao (2023)<doi:10.1080/24754269.2023.2205802>, and Bannick, Shao, Liu, Du, Yi, and Ye (2024)<doi:10.48550/arXiv.2306.10213>.

Authors:Liming Li [aut, cre], Marlena Bannick [aut], Daniel Sabanes Bove [aut], Dong Xi [aut], Ting Ye [aut], Yanyao Yi [aut], Gregory Chen [ctb], Gilead Sciences, Inc. [cph, fnd], F. Hoffmann-La Roche AG [cph, fnd], Merck Sharp & Dohme, Inc. [cph, fnd], AstraZeneca plc [cph, fnd], Eli Lilly and Company [cph, fnd], Novartis Pharma AG [cph, fnd], The University of Washington [cph, fnd]